The World Health Organization released comprehensive guidelines for using GLP-1 receptor agonists to treat obesity, affecting over 1 billion people globally. The recommendations position obesity as a chronic, relapsing disease requiring medical intervention rather than lifestyle changes alone. GLP-1 medications like semaglutide and liraglutide work by mimicking hormones that regulate blood sugar and slow gastric emptying, leading to reduced appetite and significant weight loss. The guidelines establish clinical criteria for prescribing these medications, emphasizing their role alongside diet and exercise for patients with BMI over 30 or over 27 with comorbidities. WHO stressed the importance of equitable access, as these medications currently cost thousands annually and remain unavailable in many low- and middle-income countries. The guidelines also address safety monitoring, contraindications, and the need for long-term treatment sustainability. This represents a major shift in global obesity treatment paradigms, formally recognizing pharmacotherapy as essential for managing severe obesity. The recommendations aim to standardize care globally while highlighting the urgent need for affordable access to these breakthrough medications in underserved populations.